Elevance Health (NYSE:ELV) Posts Earnings Results, Beats Expectations By $0.04 EPS

Elevance Health (NYSE:ELV) posted its earnings results on Thursday. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.80 by $0.04, Zacks reports. Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. Elevance Health updated its FY 2025 guidance to 34.150-34.850 EPS.

Elevance Health Trading Up 0.0 %

ELV opened at $401.43 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.50 and a quick ratio of 1.50. The company’s 50 day simple moving average is $386.21 and its two-hundred day simple moving average is $462.34. The firm has a market capitalization of $93.10 billion, a price-to-earnings ratio of 14.63, a price-to-earnings-growth ratio of 1.11 and a beta of 0.84. Elevance Health has a 1-year low of $362.21 and a 1-year high of $567.26.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 25th. Shareholders of record on Monday, March 10th will be issued a $1.71 dividend. This is an increase from Elevance Health’s previous quarterly dividend of $1.63. The ex-dividend date is Monday, March 10th. This represents a $6.84 dividend on an annualized basis and a yield of 1.70%. Elevance Health’s dividend payout ratio is presently 23.77%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ELV shares. TD Cowen decreased their price objective on shares of Elevance Health from $589.00 to $484.00 and set a “buy” rating for the company in a research report on Monday, October 21st. Wells Fargo & Company reduced their price target on Elevance Health from $593.00 to $495.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Morgan Stanley dropped their price objective on Elevance Health from $643.00 to $551.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. StockNews.com upgraded Elevance Health from a “hold” rating to a “buy” rating in a research report on Friday, January 17th. Finally, Truist Financial decreased their target price on Elevance Health from $520.00 to $480.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and a consensus price target of $525.60.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.